REVACCINATION WITH DIFFERENT COVID-19 VACCINE; NUMBNESS IN LEFT ARM AND HAND, FROM MIDWAY BETWEEN THE ELBOW TO THE TIP OF THUMB; NUMBNESS ABOVE THE LEFT LIP OF FACE; SUSPECTED COVID-19 INFECTION; CHANGE IN TASTE (HEAVILY METALLIC); This spontaneous report received from a patient through other manufacturer (Pfizer Inc.) concerned a 70 year old elderly. The patient's height, and weight were not reported. The patient's past medical history included: stroke, and concurrent conditions included: unspecified drug allergy, and other pre-existing medical conditions included: The patient stated he was not taking any other medication or products within 2 weeks of starting covid-19 treatment (Paxlovid). The patient previously received covid-19 vaccine ad26.cov2.s (Dose number in series 1) (suspension for injection, route of admin not reported, batch number: 1502072 expiry: UNKNOWN) dose was not reported, 1 total administered on 11-MAR-2021 to left arm for covid-19 prophylaxis. It was unknown whether patient had any adverse events following covid-19 vaccine ad26.cov2.s (Dose number in series 1). The patient received second dose of covid-19 vaccine ad26.cov2.s (Dose number in series 2) (unspecified manufacturer) (suspension for injection, route of admin, batch number and expiry date were not reported) dose, start therapy date were not reported, 1 total administered for covid-19 prophylaxis. Age at time of vaccination 69 years old. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. It was unknown whether patient had any adverse events following covid-19 vaccine ad26.cov2.s (Dose number in series 2). The patient also received third dose non-company suspect vaccine Pfizer Biontech (tozinameran) (Dose number in series 3) (form of admin, route of admin were not reported, batch number: FP7135 expiry: UNKNOWN) dose was not reported, administered on 23-NOV-2021 to left arm for covid-19 prophylaxis. It was unknown whether patient had any adverse events following Pfizer Biontech (tozinameran) (Dose number in series 3). The patient also received fourth dose non-company suspect vaccine Pfizer Biontech (tozinameran) (Dose number in series 4) (form of admin, route of admin were not reported, batch number: FH8027 expiry: UNKNOWN) dose was not reported, administered on 10-JUN-2022 to left arm for covid-19 prophylaxis which was associated with revaccination with different covid-19 vaccine (Dose number in series 4). No concomitant medications were reported.  On an unspecified date in JUN-2022, the patient experienced suspected covid-19 infection (Dose number in series 4). The patient started taking treatment with non-company suspect drugs Paxlovid (nirmatrelvir/ritonavir) (form of admin, route of admin, batch number and expiry were not reported) dose and frequency were not reported from 26-JUN-2022 to 30-JUN-2022 for treatment of covid-19. On an unspecified date in JUN-2022, several hours after the first dose of paxlovid, the patient experienced change in taste (heavily metallic), numbness in left arm and hand, from midway between the elbow to the tip of thumb, and numbness above the left lip of face (Dose number in series 4). The action taken with covid-19 vaccine ad26.cov2.s, tozinameran and tozinameran was not applicable; and action taken with nirmatrelvir/ritonavir was not reported. The patient recovered from change in taste (heavily metallic) on 01-JUL-2022, had not recovered from numbness in left arm and hand, from midway between the elbow to the tip of thumb, and numbness above the left lip of face, and the outcome of suspected covid-19 infection and revaccination with different covid-19 vaccine was not reported. This report was non-serious.